The economist thinks the Fed ought to pay more attention to financial markets when setting interest rates.The Fedread more
U.S. President Donald Trump's latest tariff increase — and Beijing's plans to counter them — are hitting U.S. companies in China, according to a joint survey this month by...China Economyread more
"We are also constantly watching whether the trade war will turn into a tech war," Ma said Tuesday, according to a CNBC translation of his Chinese remarks published by a locak...China Economyread more
Kohl's, J.C. Penney and Nordstrom release disappointing earnings news, putting a damper on their sector.Retailread more
Bezos's comments give a rare glimpse into his interest in the auto industry. Amazon recently invested in two self-driving start-ups.Technologyread more
While investing often seems like a contrarian game where going against the flow feels like the better bet, the reality is that investors who bought the most-favored stocks...Hedge Fundsread more
Talks between the world's two largest economies have stalled after each nation lobbied higher tariffs on the other's imports.Traderead more
"Pretty much the entire suite of apps that 'talk' over the internet could be vulnerable," said Tom Uren, a senior analyst at the Australian Strategic Policy Institute's...Cybersecurityread more
A Chinese official in Hong Kong is urging the quick passage of legal measures to allow fugitives to be transferred to the mainland.China Politicsread more
GAC Motor said its delaying its launch in the U.S. but had no timeline when it could launch there.Autosread more
The U.S. administration is considering limits to Chinese video surveillance firm Hikvision's ability to buy U.S. technology, the New York Times reported on Tuesday, deepening...World Politicsread more
(Adds details on Shingles vaccine)
May 1 (Reuters) - GlaxoSmithKline Plc reported better-than-expected first-quarter revenue and earnings on Wednesday, as sales of the British drugmaker's fast-growing shingles vaccine surged another 60 percent.
Sales of Shingrix, the vaccine launched in 2017, were 357 million pounds in the first quarter, up 61.5 percent from a fourth quarter in which they also doubled.
That pushed GSK's turnover to 7.66 billion pounds ($10 billion) in the quarter from 7.22 billion pounds a year earlier and above a company-provided consensus https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus of analysts' forecasts of 7.56 billion pounds.
Adjusted operating profit was 30.1 pence per share in the quarter versus expectations of 26.1 pence per share.
"We have made a strong start to 2019, which is an important year of execution for GSK, with growth in sales, operating margins and earnings per share in Q1, in line with our expectations," Chief Executive Emma Walmsley said in a statement.
Since taking over in April 2017, Walmsley has been streamlining GSK's operations and spinning off or selling units including its consumer health division to focus on expanding its drug pipeline - notably for cancer and HIV medicines - and developing vaccines.
The company, which backed its 2019 forecast of a decline in adjusted earnings of 5 to 9 percent, said its quarterly earnings were hurt by continuing price pressure and other investments in promotional product support, particularly for new launches.
($1 = 0.7654 pounds) (Reporting by Pushkala Aripaka and Ankur Banerjee in Bengaluru Editing by Saumyadeb Chakrabarty and Patrick Graham)